BiondVax leases site for universal flu vaccine plant in Israel

By Gareth Macdonald contact

- Last updated on GMT

iStock/robeo
iStock/robeo

Related tags: Influenza, Flu vaccine

BiondVax Pharmaceuticals Ltd has leased space for a manufacturing plant with capacity to make tens of millions of doses of its flu vaccine, M-001.

The facility, which will be built  is at a site at the Jerusalem BioPark in Israel, is intended to make commercial supplies of the vaccine if it goes on to be approved. The lease is for an initial period of10 years.

Construction of the facility will be partly supported by a grant from Israel’s Ministry of Economy and Industry and a €20m ($22m) loan from the European Investment Bank (EIB) that BiondVax secured last month.

M-001 is designed to protect against both seasonal and pandemic flu strains. It consists of nine widely conserved influenza epitopes chosen to allow it to protect against a wide range of viruses.

BiondVax plans to move the vaccine into Phase III, although it has not said when.

In 2015​, the firm contracted Cytovance Biologics to help it scale up the manufacturing process used to produce the vaccine for clinical trials.

Related topics: Upstream Processing, Facilities

Related news

Show more

Related products

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars